CTRI/2011/09/002030
Completed
Phase 2
Comparative Efficacy, Safety and Tolerability of Silver Sulfadiazine Cream (Nanonized) and Silverex Cream in the Prophylaxis of Infection in Burn Wounds - An Open-label, Randomized, Pilot Study
Ranbaxy Laboratories Ltd0 sites36 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Ranbaxy Laboratories Ltd
- Enrollment
- 36
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Subjects who have given written informed consent to participate in the study.
- •2\. Subjects of either sex aged between 18 and 65 years (both inclusive) with partial thickness burns of thermal origin covering 10% of the TBSA and suitable for outpatient management.
- •3\. Subjects in whom burn injury is 24 hours old at the time of screening.
- •4\. Subjects with clean, non\-infected wound as judged by the investigator.Presence of infection will be judged clinically by symptoms and signs that include purulent drainage, erythema, warmth, exudation, malodor, pain and/or fever.
Exclusion Criteria
- •1\.Subjects with history of hypersensitivity to silver sulfadiazine, other sulfonamides, chlorhexidine or any of the excipients of study formulations\#.
- •2\.Subjects with burn wounds associated with chemical, electrical or inhalational injury.
- •3\.Subjects with full thickness burns (a burn involving destruction of the entire epidermis and dermis, leaving no residual epidermal cells to repopulate) or circumferential burns (a burn which encircles an entire body part) or superficial burn (a burn which remains confined to the epidermis).
- •4\.Subjects with burns involving genitalia, head (including face), perineum or major joints.
- •5\.Subjects with burns of hands or feet likely to cause functional impairment.
- •6\.Subjects with burn wounds not expected to heal within 21 days or requiring systemic antimicrobial treatment or surgical intervention (except surgical debridement) during the study.
- •7\.Subjects with burn wounds expected to heal in less than 7 days.
- •8\.Subjects with burns and concomitant trauma (such as fractures) in which the burn injury poses the greatest risk of morbidity and mortality.
- •9\.Burn injury in subjects with preexisting medical disorders (e.g., diabetes mellitus, cancer or other immunocompromising conditions) that could complicate management, prolong recovery, or affect mortality.
- •10\.Subjects who are under treatment with topical or systemic steroid medications or immunosuppressive agents.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
anonized Silver Sulfadiazine Cream in prevention of Infections in Burn woundsHealth Condition 1: null- Prophylaxis of Infection in Burn WoundsCTRI/2014/11/005188Sun Pharmaceutical Industries Limited250
Not yet recruiting
Not Applicable
Comparison of two inject able iron preparations for treatment of iron deficiency anemia in pregnancyCTRI/2019/02/017553Department of Obstetrics and Gynecology
Not yet recruiting
Not Applicable
Effect of products on pimplesCTRI/2024/08/072208KOP research centre private limited
Completed
Phase 3
Cefozopran injection in treatment of community acquired pneumoniaCTRI/2013/02/003366Ranbaxy Research Laboratories100
Completed
Phase 3
Cefozopran injection in treatment of complicated urinary tract infection and pyelonephritisHealth Condition 1: null- Complicated urinary tract infection and PyelonephritisCTRI/2013/02/003340Ranbaxy Laboratories Ltd100